These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
457 related articles for article (PubMed ID: 35702932)
1. Real-world treatment patterns of metastatic non-small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors. Shenolikar R; Liu S; Shah A; Tse J; Cao Y; Near A Cancer Med; 2023 Jan; 12(1):159-169. PubMed ID: 35702932 [TBL] [Abstract][Full Text] [Related]
2. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors. Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357 [TBL] [Abstract][Full Text] [Related]
3. Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study. Turnsek N; Devjak R; Edelbaher N; Osrajnik I; Unk M; Vidovic D; Jeric T; Janzic U Radiol Oncol; 2022 Aug; 56(3):371-379. PubMed ID: 35853681 [TBL] [Abstract][Full Text] [Related]
4. Real-world outcomes among patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in the first-line setting. Apple J; Shenolikar R; De Silva K; Sun P; Spira A Cancer Med; 2023 Jun; 12(12):13415-13425. PubMed ID: 37306623 [TBL] [Abstract][Full Text] [Related]
5. Comparison of clinical outcomes of osimertinib and first-generation EGFR-tyrosine kinase inhibitors (TKIs) in TKI-untreated EGFR-mutated non-small-cell lung cancer with leptomeningeal metastases. Tamura K; Yoshida T; Masuda K; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Ohe Y ESMO Open; 2023 Aug; 8(4):101594. PubMed ID: 37517364 [TBL] [Abstract][Full Text] [Related]
6. Study of patient characteristics, treatment patterns, Winfree KB; Sheffield KM; Cui ZL; Sugihara T; Feliciano J Curr Med Res Opin; 2022 Jan; 38(1):91-99. PubMed ID: 34544302 [TBL] [Abstract][Full Text] [Related]
7. Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence. Lu S; Shih JY; Jang TW; Liam CK; Yu Y Adv Ther; 2021 May; 38(5):2038-2053. PubMed ID: 33730350 [TBL] [Abstract][Full Text] [Related]
8. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Gelatti ACZ; Drilon A; Santini FC Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888 [TBL] [Abstract][Full Text] [Related]
9. Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for EGFR mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01). Uryu K; Imamura Y; Shimoyama R; Mase T; Fujimura Y; Hayashi M; Ohtaki M; Otani K; Hibino M; Horiuchi S; Fukui T; Fukai R; Chihara Y; Iwase A; Yamada N; Tamura Y; Harada H; Shinozaki N; Tsuya A; Fukuoka M; Minami H Jpn J Clin Oncol; 2024 Mar; 54(3):319-328. PubMed ID: 37997468 [TBL] [Abstract][Full Text] [Related]
10. Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01. Hibino M; Imamura Y; Shimoyama R; Fukui T; Fukai R; Iwase A; Tamura Y; Chihara Y; Okabe T; Uryu K; Okuda T; Taguri M; Minami H Target Oncol; 2024 Sep; ():. PubMed ID: 39302602 [TBL] [Abstract][Full Text] [Related]
11. Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs. Chen HY; Chen CH; Liao WC; Lin YC; Chen HJ; Hsia TC; Cheng WC; Tu CY BMC Pulm Med; 2024 Oct; 24(1):517. PubMed ID: 39415161 [TBL] [Abstract][Full Text] [Related]
12. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre. Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049 [TBL] [Abstract][Full Text] [Related]
13. Ideal sequencing in Stage IV epidermal growth factor receptor mutant Non-Small-Cell Lung Cancer. Walia M; Singhal MK; Kamle MS Indian J Cancer; 2022 Mar; 59(Supplement):S80-S89. PubMed ID: 35343193 [TBL] [Abstract][Full Text] [Related]
14. EGFR-TKI rechallenge in patients with EGFR-mutated non-small-cell lung cancer who progressed after first-line osimertinib treatment: A multicenter retrospective observational study. Araki T; Kanda S; Obara M; Agatsuma T; Kakizaki Y; Hama M; Yamamoto H; Takada M; Yamamoto M; Matsuo A; Kondo D; Komatsu M; Sonehara K; Tateishi K; Hanaoka M; Koizumi T Respir Investig; 2024 Mar; 62(2):262-268. PubMed ID: 38245931 [TBL] [Abstract][Full Text] [Related]
15. Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting. Kraskowski O; Stratmann JA; Wiesweg M; Eberhardt W; Metzenmacher M; Schmid KW; Herold T; Schildhaus HU; Darwiche K; Aigner C; Stuschke M; Laue K; Zaun G; Kasper S; Hense J; Sebastian M; Schuler M; Pogorzelski M J Cancer Res Clin Oncol; 2023 Sep; 149(11):9243-9252. PubMed ID: 37198447 [TBL] [Abstract][Full Text] [Related]
16. Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations. Hayashi H; Nadal E; Gray JE; Ardizzoni A; Caria N; Puri T; Grohe C Clin Lung Cancer; 2022 Jan; 23(1):e69-e82. PubMed ID: 34865963 [TBL] [Abstract][Full Text] [Related]
17. EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors. Chiang AC; Fernandes AW; Pavilack M; Wu JW; Laliberté F; Duh MS; Chehab N; Subramanian J BMC Cancer; 2020 Apr; 20(1):356. PubMed ID: 32345265 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer. Aguiar PN; Haaland B; Park W; San Tan P; Del Giglio A; de Lima Lopes G JAMA Oncol; 2018 Aug; 4(8):1080-1084. PubMed ID: 29852038 [TBL] [Abstract][Full Text] [Related]
19. Survival outcomes of east Asian patients with advanced non-small cell lung cancer treated with first-line EGFR tyrosine kinase inhibitors: A network meta-analysis of real-world evidence. Chang HC; Huang KT; Tseng CC; Chen YM; Lai CH; Chang YP; Chen YC; Chuang HY; Wang CC Thorac Cancer; 2023 Nov; 14(32):3217-3225. PubMed ID: 37704454 [TBL] [Abstract][Full Text] [Related]
20. Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective Analysis. Mitsuya S; Tsuruoka K; Kanaoka K; Funamoto T; Tsuji H; Matsunaga N; Nakamura T; Tamura Y; Imanishi M; Ikeda S; Fujisaka Y; Goto I; Imagawa A Anticancer Res; 2021 Oct; 41(10):5137-5145. PubMed ID: 34593465 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]